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Sirolimus is an immunosuppressant commonly
used in solid organ transplantation as an alternative
to corticosteroids or calcineurin inhibitors. Common
side effects include hyperlipidemia, arthralgias, and
noncardiac peripheral edema. Pulmonary toxicity is
increasingly recognized after solid organ transplants
[1-3]. Here we report the first case of sirolimus-associ-
ated pneumonitis (SAP) in a peripheral blood stem cell
transplant (PBSCT) patient.
A 21-year-old Puerto Rican woman with homozy-
gous sickle cell disease (SCD) had a history of stroke as
a child and frequent vaso-occlusive crises while on hy-
droxyurea. She met inclusion criteria and enrolled in
an institutional review board-approved nonmyeloabla-
tive peripheral blood stem cell transplant study at the
Clinical Center of the National Institutes of Health.
She tolerated a low-dose radiation-based conditioning
regimen and received a T-replete graft with 10  106
per kilogramCD341 cells from herHLA-matched sis-
ter. She experienced no sickle-related complications,
and achieved prompt hematopoietic recovery. She
was maintained on sirolimus only, targeting a trough
level of 15-20 ng/mL. One year later, she was free of
SCD: hemoglobin was 12 g/dL, hemoglobin electro-
phoresis was stable and compatible with her sickle trait
donor, and 100% of peripheral blood CD14/15 leuko-
cytes were of donor origin. She was regularly phlebo-
tomized to correct transfusional iron overload.
Sixteen months after the transplant, she developed
cough, dyspnea on exertion, and progressed to debili-
tating dyspnea over a 4-week interval, but never
required supplemental oxygen. There were no ante-
cedent infections, CMV reactivation, acute or chronic
GVHD (aGVHD, cGVHD), or other transplant-re-
lated complications. Upon admission to evaluate her
dyspnea, she was afebrile with normal vital signs; her
resting pulse oximetry was 99% to 100% on room
air, which decreased to 95% after ambulating 100 me-
ters. Her echocardiogram showed a normal ejection256fraction, normal valvular function, and no pulmonary
hypertension. Pulmonary function tests showed a se-
vere obstructive and restrictive defect. Computerized
tomography (CT) of the chest showed fine, hazy, bi-
lateral, lower lobe infiltrates; no bronchial dilatation
or thickening, peribronchial nodules or consolidations
were observed. Bronchoalveolar lavage recovered
numerous mononuclear and few granulocytic cells;
studies for bacteria, atypical organisms, acid fast or-
ganisms, fungi, pneumocystis jiroveci (PCP), CMV,
and other viruses, were all negative. Sirolimus-associ-
ated pneumonitis was suspected, sirolimus was tapered
off over 3 days, and oral cyclosporine was initiated;
systemic corticosteroid was not administered. Albu-
terol, ipratroprium, and corticosteroid inhalers were
administered. One week later, she had a dramatic re-
sponse: her subjective dyspnea improved and the dis-
tance of her 6-minute walk increased from 195 to
330 meters. She was discharged to home after 2 weeks
of hospitalization. Six to 8 months later, her respira-
tory status, exercise tolerance, PFTs, and CT scans
all returned to pretransplant levels (Figure 1A and B).
0.5
1.5
2.5
3.5
4.5
0 6 12 16 16.5 18 20 22 24
0
20
40
60
80
100
FVC FEV1
FEF 25-75% FEV1/FVC
Li
te
rs
 o
f l
un
g 
vo
lu
m
e
Months after transplant
%
 FEV1/FVC
Li
te
rs
 o
f l
un
g 
vo
lu
m
e
Months after transplant
D
LCO
 m
L/m
m
Hg/m
in
0
1
2
3
4
0 6 12 16 16.5 18 20 22 24
0
5
10
15
20
25
Vt VC
IC DLCO
A
B
Figure 1. (A) Pulmonary forced spirometry. FVC5 forced vital ca-
pacity, FEV15 forced expiratory volume in 1 second, FEF5 forced
expiratory flow in liters/sec. (B) Pulmonary slow spirometry.
VC 5 vital capacity, IC 5 inspiratory capacity, Vt 5 tidal volume,
DLCO 5 lung diffusing capacity of carbon monoxide.
Sirolimus Associated Pneumonitis in a Sickle Cell Patient 257Late noninfectious pulmonary complications fol-
lowing allogeneic PBSCT often require aggressive
treatment including corticosteroids and monoclonal
antibodies, and are associated with significant morbid-
ity and mortality [4]. Although our patient demon-
strated classic features of bronchiolitis obliterans
(BO) and bronchiolitis obliterans with organizing
pneumonia (BOOP) [5], her symptoms resolved in 1-
2 weeks without intensifying immunosuppression.
Her follow-up PFTs steadily improved, and imaging
studies showed no indication of relapse or progression,
which are uncharacteristic of BO and BOOP.
Although our patient demonstrated both restrictive
and obstructive changes, obstructive pulmonary func-
tion tests are less commonly observed in SAP [6].
Our patient’s underlying SCDmay have been a predis-
posing factor for the observed obstruction, because
SCD is commonly associated with asthma [7-9]. This
case also highlights that with the increase use of siroli-
mus in stem cell transplantation [10], SAP may be
increasingly recognized as in solid-organ recipients.
Furthermore, the clinical presentation may differ in
this setting. Finally, sirolimus withdrawal can be utilized
as a diagnostic test before committing to long-term
aggressive corticosteroid and/or monoclonal antibody
therapies.
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